OncoMark is focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.read more »
Gene expression profiling test for early-stage breast cancer prognosis
OncoMark Announces Results of Key Studies on Clinical Performance of Prognostic Test for Early Stage Breast Cancer
OncoMark Ltd, an Irish diagnostics company, today announced the results of two key studies on the clinical performance of its OncoMasTR test.
OncoMark announce the appointment of Professor John Crown as the company’s Chief Medical Officer (CMO)
OncoMark Ltd, an Irish diagnostics company focused on the development of novel panels of cancer biomarkers to aid treatment decisions for cancer patients, today announced the appointment of Professor John Crown as the company’s Chief Medical Officer (CMO).
OncoMark to Present Two Studies on Prognostic Test for Early Stage Breast Cancer at ASCO 2018 in Chicago
Presentations will highlight the clinical performance of the OncoMasTR test in the TransATAC and TAILORx tissue bank cohorts
January 2018: OncoMark are attending the Arab Health Exhibition and Congress in Dubai
OncoMark CEO Mr. Des O’Leary and OncoMark Business Development Manager Mr. Fergus Fleming are attending the Arab Health Exhibition and Congress at the Dubai International Convention and Exhibition Centre from the 29th January to the 1st February 2018.
December 2017: OncoMark are attending the San Antonio Breast Cancer Symposium (SABCS)
OncoMark initiate testing of TransATAC cohort
OncoMark have initiated clinical validation of the OncoMasTR test using tumour samples from the TransATAC Tissue Resource.
OncoMark attended the European Society of Medical Oncology (ESMO) 2017 Congress
OncoMark Website Relaunch – New Look and Focus
OncoMark are pleased to announce the launch of their newly designed website www.oncomark.com. The website provides an enhanced user experience to our target audience to access information relating to OncoMark and the OncoMasTR test.
Irish-led research discovers potential new way to treat aggressive type of breast cancer
Study gives new hope of targeted treatment for triple negative breast cancer
Research led by Prof. William Gallagher, Director of BREAST-PREDICT and Chief Scientific Officer of OncoMark, has found a potential new approach to treating one of the most difficult-to-treat forms of breast cancer, which currently has limited treatment options.